Consistent with this, reanalysis of the TCGA PRAD cohort (n = 497) showed that tumor T-stage progression was associated with SRD5A1 and HSD17B3 gene amplification and gain, but shallow or deep deletion of SHBG and HSD17B2 genes (Figure 1D). The gene discussed is SRD5A1; the disease is neoplasm.